ImmunityBio Stock Climbs Thursday: What's Going On?
ImmunityBio shares are trading higher Thursday after the FDA approved expansion for its bladder cancer therapy ANKTIVA.
Share
Why It Matters
The FDA said ImmunityBio's cancer medicine can treat more patients. When a medicine gets approved for more uses, it means the company might earn more money.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.